Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Current Quarter	$-0.14	Next Quarter	$-0.17
Current Year	$-0.64	Next Year	$-0.51
QoQ Growth	-21.4%	YoY Growth	+20.3%
3Y EPS CAGR	+34.9%	Target Price	$10.30
Consensus	Buy	Upside	+61.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AQST	$6.38	+2.33%	890.25K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AQST	$6.38	+2.3%	890.25K
3
4
5
6

AQST

AQST

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Aquestive Therapeutics Inc. Data in Excel

Get Aquestive Therapeutics Inc. Data in Excel